MedTrace Logo

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

NCT02211014 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-07-31

Study results available
· View outcomes & findings →

Summary

To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)

Conditions

  • Multiple Myeloma (MM)

Interventions

DRUG

acalabrutinib

Sponsors & Collaborators

  • Acerta Pharma, LLC

    collaborator OTHER

  • Acerta Pharma BV

    lead INDUSTRY

Principal Investigators

  • Acerta Clinical Trials · 1-888-292-9613

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-04-26
Completion
2019-04-26

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02211014 on ClinicalTrials.gov